2024
Deciphering craniopharyngioma subtypes: Single-cell analysis of tumor microenvironment and immune networks
Matsuda T, Kono T, Taki Y, Sakuma I, Fujimoto M, Hashimoto N, Kawakami E, Fukuhara N, Nishioka H, Inoshita N, Yamada S, Nakamura Y, Horiguchi K, Miki T, Higuchi Y, Tanaka T. Deciphering craniopharyngioma subtypes: Single-cell analysis of tumor microenvironment and immune networks. IScience 2024, 27: 111068. PMID: 39483146, PMCID: PMC11525618, DOI: 10.1016/j.isci.2024.111068.Peer-Reviewed Original ResearchTumor microenvironmentAnalysis of tumor microenvironmentImmune responseOccurrence of diabetes insipidusExpression of pro-inflammatory markersCell-cell interactionsPro-inflammatory markersComprehensive cell atlasM2 macrophage ratioSquamous papillaryDiabetes insipidusTumor cellsSingle cell RNA sequencingMacrophage ratioM1 macrophagesM2 macrophagesPituitary structureCell RNA sequencingCellular compositionSingle-cell clusteringCell typesDiverse cell typesTumorGene expression patternsMolecular characteristicsIncreased autoreactivity and maturity of EBI2+ antibody-secreting cells from nasal polyps
Bai J, Kato A, Hulse K, Wechsler J, Gujar V, Poposki J, Harmon R, Iwasaki N, Wang B, Huang J, Stevens W, Conley D, Welch K, Kern R, Peters A, Eisenbarth S, Schleimer R, Tan B. Increased autoreactivity and maturity of EBI2+ antibody-secreting cells from nasal polyps. JCI Insight 2024, 9: e177729. PMID: 39253973, PMCID: PMC11385095, DOI: 10.1172/jci.insight.177729.Peer-Reviewed Original ResearchConceptsAntibody-secreting cellsGene Ontology biological processesSingle-cell RNA-seq analysisApoptosis pathwayNumbers of antibody-secreting cellsAnti-dsDNA IgGPlasma cell differentiationBiological processesCell differentiationNasal polypsGenesMolecular characteristicsNF-kBProliferative cellsMolecular featuresCellsAnti-double-stranded DNAIgG antibody-secreting cellsEBI2B cellsXBP1Recurrent NPElevated numbersDNAIncreased autoreactivityClinical Biochemistry of Serum Troponin
Gokhan I, Dong W, Grubman D, Mezue K, Yang D, Wang Y, Gandhi P, Kwan J, Hu J. Clinical Biochemistry of Serum Troponin. Diagnostics 2024, 14: 378. PMID: 38396417, PMCID: PMC10887818, DOI: 10.3390/diagnostics14040378.Peer-Reviewed Original ResearchAcute coronary syndromeFalse negative test resultsPoint of care assayInterpretation of serum levelsNegative test resultsTroponin complexChest painInterpretation of assay resultsSerum levelsClinical workupCoronary syndromeTn assaysMyocardial injuryTest characteristicsClinical settingCare assaysTroponinMeasurement assaysMolecular characteristicsPotential causesAssay resultsAssayMolecular structureFalse resultsConstituent proteins
2023
Predictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaPredictive biomarkersEra of treatment optionsCharacteristics of renal cell carcinomaPrediction of treatment responseOptimal therapeutic pathwayTargeted systemic therapyImmuno-oncology agentsRoutine clinical useSystemic therapyAdvanced diseaseClinical benefitTreatment responseTreatment optionsClinical useTherapeutic pathwaysCarcinomaPatientsBiomarkersMolecular characteristicsTherapyPatient-derived glioblastoma cell lines with conserved genome profiles of the original tissue
Kim S, Cho Y, Shin Y, Yu H, Chowdhury T, Kim S, Yi K, Choi C, Cha S, Park C, Ku J. Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue. Scientific Data 2023, 10: 448. PMID: 37438387, PMCID: PMC10338444, DOI: 10.1038/s41597-023-02365-y.Peer-Reviewed Original ResearchConceptsCell linesPatient-derived glioblastoma cell linesPatient-derived cell linesWhole exome sequencing datasetsExome sequencing datasetsGBM cell linesGlioblastoma cell linesSequence dataGenomic featuresLethal intracranial tumorSequencing technologiesSequencing datasetsMolecular markersWES datasetsGenome profilesMutational signaturesDruggable targetsNumber alterationsBiological credibilityGenomic profilesBiological platformMolecular characteristicsOriginal tissueTumor tissueGlioblastomaBiallelic mutations in LSS in autosomal‐recessive mutilating palmoplantar keratoderma
Zhou S, Jiang X, Zhu Y, Yang J, Yuan C, Chen M, Zhou Q, Lin Z, Li M. Biallelic mutations in LSS in autosomal‐recessive mutilating palmoplantar keratoderma. Experimental Dermatology 2023, 32: 699-706. PMID: 36811447, DOI: 10.1111/exd.14774.Peer-Reviewed Original ResearchConceptsLanosterol synthaseBiallelic mutationsLanosterol synthase genesPalmoplantar keratodermaPartial enzymatic activityHeterogeneous genetic diseaseExpression levelsMutilating palmoplantar keratodermaPathway of cholesterolBiosynthesis pathwayReduced expression levelsBiallelic variantsWild typeEnzymatic activityGenetic diseasesAutosomal-recessiveGenetic counselingMutationsMolecular characteristicsThin layer chromatographyLayer chromatographyMutantsBiosynthesisMale patientsChinese patientsChapter 3 Single-cell transcriptomics
Marczyk M, Kujawa T, Papiez A, Polanska J. Chapter 3 Single-cell transcriptomics. 2023, 67-84. DOI: 10.1016/b978-0-323-91810-7.00015-7.ChaptersSingle-cell transcriptomicsSingle-cell technologiesCell trajectory inferenceGene expression dataSimilar cell typesTranscriptional signalsCancer cell line dataRNAseq dataGene expressionCellular heterogeneitySequencing platformsBreast cancer cell line dataExpression dataCell line dataGroups of cellsTrajectory inferenceCell typesIndividual cellsMolecular characteristicsProper processingCellsTranscriptomicsGenesExpressionCertain steps
2021
Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings
Arora S, Harmath C, Catania R, Mandler A, Fowler KJ, Borhani AA. Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings. Abdominal Radiology 2021, 46: 3698-3707. PMID: 34091729, DOI: 10.1007/s00261-021-03151-3.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaExtrahepatic diseaseMetastatic diseaseManagement of patientsEarly metastatic diseaseCourse of treatmentExtrahepatic spreadDefinitive treatmentInitial presentationTreatment optionsPrecise stagingMetastatic pathwaysTumor biologySystemic spreadMolecular derangementsPatientsDiseasePotential roleDifferent pathwaysMolecular characteristicsTreatmentPathwayCarcinomaDerangementStaging
2020
Clinical neuro-oncology for the neurologist.
Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.Peer-Reviewed Original ResearchNeuro-oncologyReclassification of tumorsClinical neuro-oncologyClinical practiceClinically relevant pointsCNS lymphomaNeuro-oncology patientsBrain metastasesInfiltrating gliomasBrain tumorsStandard managementAdult neurologistsTumorPatient carePatientsMolecular characteristicsEvolving fieldNeurologistsBrainLymphomaMetastasisMeningiomasGliomaCNSClinicSyndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer.
Wu Y, Huang H, Fervers B, Lu L. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer. Pancreas 2020, 49: 1187-1194. PMID: 32898003, DOI: 10.1097/mpa.0000000000001654.Peer-Reviewed Original ResearchConceptsSyndecan-1Patient survivalPancreatic cancerAdjusted hazard ratioPancreatic cancer patientsKRAS somatic mutationsSDC1 mRNASomatic mutationsHazard ratioCancer patientsClinical dataSurvival analysisKRASPatientsKyoto EncyclopediaKRAS mRNAElevated mortalityGenomes (KEGG) pathway analysisCancerPathway analysisLower methylationMolecular characteristicsSurvivalMRNANegative correlation
2019
Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors
Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019, 14: 437-445. PMID: 31472741, DOI: 10.1016/j.cpet.2019.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFluorodeoxyglucose F18HumansInfusions, Intra-ArterialLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicMultimodal ImagingNeoplasm MetastasisPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificitySurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeTumor MicroenvironmentConceptsTransarterial chemoembolizationLiver tumorsFluorine-18 fluorodeoxyglucose PETEfficacy of embolotherapyCross-sectional imaging techniquesMetastatic liver tumorsCancer cell glycolysisLocal recurrenceFluorodeoxyglucose PETTumor necrosisLiver cancerMorphologic changesCell glycolysisEmbolotherapyTumorsMonitoring responseIndividual molecular characteristicsMolecular characteristicsImaging techniquesChemoembolizationResponsePatientsRecurrencePETTherapy
2018
Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity
Correa BRS, Hu J, Penalva LOF, Schlegel R, Rimm DL, Galante PAF, Agarwal S. Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity. Scientific Reports 2018, 8: 4097. PMID: 29511269, PMCID: PMC5840339, DOI: 10.1038/s41598-018-22427-1.Peer-Reviewed Original ResearchConceptsDrug target identificationNon-small cell lung cancerCancer cell biologyIntra-tumor genetic heterogeneityDrug discovery effortsMutant-allele tumor heterogeneity (MATH) scoreCell biologyWhole-exome sequencingCell heterogeneityNumber variationsPatient-derived cell culturesDiscovery effortsCR cellsCancer cell linesIntra-tumoral heterogeneityGenetic heterogeneityCell linesExome sequencingTarget identificationCell lung cancerLung cancer modelBiologyCell culturesMolecular characteristicsPrimary cultures
2016
Chapter 40 Genomic Landscape of Brain Tumors
Clark V, Youngblood M, Bai H, Günel J, Günel M. Chapter 40 Genomic Landscape of Brain Tumors. 2016, 653-663. DOI: 10.1016/b978-0-12-800105-9.00040-8.Peer-Reviewed Original Research
2015
Future Directions and New Targets in Endometrial Cancer
Black J, Roque D, Gold L, Santin A. Future Directions and New Targets in Endometrial Cancer. Current Clinical Oncology 2015, 259-271. DOI: 10.1007/7631_2015_1.Peer-Reviewed Original ResearchEndometrial cancerNext-generation sequencingPathway aberrationsMolecular aberrationsUnique molecular characteristicsCancerNew targetsSomatic mutationsTherapyHeterogeneous somatic mutationsMolecular characteristicsCompelling evidenceGeneration sequencingRecent advancesProper classificationAberrationsTumorsDisease
2010
The Bile Salt Export Pump: Clinical and Experimental Aspects of Genetic and Acquired Cholestatic Liver Disease
Lam P, Soroka C, Boyer J. The Bile Salt Export Pump: Clinical and Experimental Aspects of Genetic and Acquired Cholestatic Liver Disease. Seminars In Liver Disease 2010, 30: 125-133. PMID: 20422495, PMCID: PMC3008346, DOI: 10.1055/s-0030-1253222.Peer-Reviewed Original ResearchConceptsBenign recurrent intrahepatic cholestasis type 2Progressive familial intrahepatic cholestasis type 2Bile salt export pumpDrug-induced cholestasisType 2Export pumpCholestatic liver diseaseBile salt secretionForms of cholestasisDifferent genetic formsLiver diseaseCholestatic disordersIntrahepatic cholestasisBSEP expressionPathophysiologic processesBSEP deficiencyAnimal modelsCholestasisGenetic formsBile saltsSalt secretionMolecular characteristicsPivotal roleCell culturesPrimary transporter
2008
Clinical and molecular characteristics of sickle cell anemia in the northeast of Brazil
Adorno E, Zanette Â, Lyra I, Seixas M, Reis M, Gonçalves M. Clinical and molecular characteristics of sickle cell anemia in the northeast of Brazil. Genetics And Molecular Biology 2008, 31: 621-625. DOI: 10.1590/s1415-47572008000400003.Peer-Reviewed Original ResearchSevere sickle cell anemiaSickle cell anemiaCell anemiaBeta S-globin gene haplotypesMean hemoglobin concentrationLow mean corpuscular volumeMean corpuscular volumeErythrocyte transfusionCerebrovascular accidentHigher mean hemoglobin concentrationHigh HbF levelsClinical dataCAR haplotypeHemoglobin concentrationCorpuscular volumeCorpuscular hemoglobinOutpatientsHbF levelsFetal hemoglobinAnemiaPCR-RFLPCarrier valuesHemoglobinGene haplotypesMolecular characteristicsMolecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. Journal Of Clinical Oncology 2008, 26: 1472-1478. PMID: 18349398, DOI: 10.1200/jco.2007.13.0062.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorDisease-Free SurvivalErbB ReceptorsErlotinib HydrochlorideFemaleHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Quinazolinesras ProteinsSuppressor of Cytokine Signaling ProteinsTreatment OutcomeConceptsProgression-free survivalBronchioloalveolar carcinomaResponse rateEGFR mutationsEGFR immunohistochemistryKRAS mutationsEpidermal growth factor receptor (EGFR) mutationsPrimary end pointEfficacy of erlotinibPhase II trialSubset of patientsCell lung cancerBAC subtypeOverall response rateKRAS mutation statusPure bronchioloalveolar carcinomaBronchioloalveolar carcinoma (BAC) subtypeMolecular characteristicsMedian OSII trialMedian survivalOverall survivalHistologic subtypeLung cancerUnivariate analysis
2007
Activation-induced Cytidine Deaminase-mediated Sequence Diversification Is Transiently Targeted to Newly Integrated DNA Substrates*
Yang SY, Fugmann SD, Gramlich HS, Schatz DG. Activation-induced Cytidine Deaminase-mediated Sequence Diversification Is Transiently Targeted to Newly Integrated DNA Substrates*. Journal Of Biological Chemistry 2007, 282: 25308-25313. PMID: 17613522, DOI: 10.1074/jbc.m704231200.Peer-Reviewed Original ResearchConceptsActivation-induced cytidine deaminaseChicken B cell line DT40B cell line DT40Cytidine deaminaseNon-Ig lociNon-Ig genesSequence diversificationDNA substratesTranscription cassetteMutation targetsCassetteMolecular characteristicsMolecular featuresDeaminaseDT40TranscriptionGenesLociDNADiversificationMutabilityTargetingIgTarget
2006
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nature Reviews Clinical Oncology 2006, 3: 621-632. PMID: 17080180, DOI: 10.1038/ncponc0636.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapyMolecular classificationBreast cancerER-positive tumorsEarly-stage diseaseNew molecular classificationRoutine clinical useAdjuvant therapyNegative diseaseEstrogen receptorIndividual patientsChemotherapyClinical usePatientsCancerDiseaseMolecular characteristicsFuture promiseTherapyTumorsReceptors
2005
Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
Lajos P, Symmans F, Hortobagyi G. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005, 12: 73-85. PMID: 15858436, DOI: 10.1007/bf02966817.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual Meeting
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply